Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I love it, bring on the bashers. This is great news! Welcome to the party!!
Tomorrow
Yes, lol
Nothing, it's just a cancellation of the public offering.
Not sure I follow your question?
Thank god the float is so small.. A bit more volume and this thing is gonna hit new highs.
The volume is starting to climb, seems mm's have their timing perfectly on course with the next PR. Must be a big one!
Yes, it's quite obvious..
More news on the way.. We're getting ready to make a run folks.
I think you meant .20.. I agree this level will vanish fairly quickly once funding is in place. Good volume today lots of accumulation into some strong hands.
ignore the children
Lots of spammers on these boards try to ignore as much as you can.
As for SBFM. We are awaiting the final transfer announcement and for a confirmation of the transfer to SBFM Canada, more news on the Garmen labs acquisition/merger and based on the last PR there should be quite a few new fiscal opportunities that should go with new funds ... I'm hoping that should give us the funds required to accelerate the Ind completion and eventual application to the FDA.
Here's one that fits well for you..
We still have a long way to go.. Sit tight.
SOUTH SAN FRANCISCO, Calif., May 30, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the publication of a peer-reviewed paper in Expert Opinion on Pharmacotherapy featuring the Company's lead product candidate, vosaroxin. In addition to an overview of the chemistry, pharmacokinetics and clinical development of vosaroxin, including the ongoing Phase 3 VALOR and Phase 2/3 LI-1 trials, the paper explores the potential advantages of vosaroxin over anthracycline therapy, including overcoming resistance mechanisms, more site-selective DNA damage, and reduced formation of DNA adducts and reactive oxygen species resulting in better tolerability. The paper, entitled "Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?" is expected to be published in the July 2013 (Volume 14, Number 10) issue of the print publication and is currently available online (click here to link).
"As the authors note, despite new understanding of the biology and genetics of acute myeloid leukemia, outcomes for patients remain poor and the need for new therapies remains urgent," said Adam R. Craig, MD, PhD, Executive Vice President, Development and Chief Medical Officer of Sunesis. "Vosaroxin, as a novel first-in-class anticancer quinolone derivative, has several potential advantages over anthracyclines and target-specific therapies. This paper offers a comprehensive review of these potential advantages in addition to discussing the clinical history and outlook for vosaroxin, including the VALOR trial, which remains on track to complete full enrollment in 2013."
Sunesis is currently evaluating vosaroxin in a pivotal Phase 3, randomized, double-blind, placebo-controlled trial, the VALOR trial, in patients with first relapsed or refractory acute myeloid leukemia (AML). The Company is also participating in a Phase 2/3 randomized, controlled trial evaluating novel treatment regimens, including two treatment arms containing vosaroxin, in newly diagnosed elderly acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) patients. The trial, known as the Less Intensive 1 (LI-1) trial, is being sponsored by Cardiff University and conducted by the United Kingdom's National Cancer Research Institute Haematological Oncology Study Group under the direction of Professor Alan K. Burnett.
Good promise yes. But, not results.. at least not yet.
Preclinical trials... There are steps and procedures involved in manufacturing/developing and testing drugs. "This is not snake oil."
Then you need funding and approvals.
Patience is key here!
Sunshine Biopharma, a pharmaceutical company, has announced that it is re-domiciling the company in Canada for expansion through acquisitions and to gain access to various financing opportunities available to Canadian corporations.
To this end, the company filed a Schedule 14-C Information Statement on 16 September 2013 and an S-4 Registration Statement on 23 October 2013.
Sunshine Biopharma CEO Dr Steve N. Slilaty noted the company is very pleased that the re-domiciling process is going smoothly.
"Re-domiciling the Company in Canada will give us access to a more favorable fiscal environment and provide with greater flexibility to execute our business plan. This will better position our Company for expansion and allow us to capitalize on growth opportunities as our Adva-27a drug candidate enters the clinic," Slilaty added.
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells.
Adva-27a is currently in the IND-Enabling stage of development. The original US patent covering Adva-27a was issued on 7 August 2012.
Unique Features of Adva-27a
Adva-27a will be the only Topoisomerase II Inhibitor on the Market.
Adva-27a can be taken orally.
Adva-27a’s initial indication will be multi-drug resistant breast cancer. Adva-27a can be used to treat other Top2 Positive Cancer Types (Prostate, Colon, Lung, Stomach, Ovarian).
Know what you own people..
Adva-27a, a novel podophyllotoxin derivative found to be effective against multidrug resistant human cancer cells.
AuthorsMerzouki A, et al. Show all Journal
Anticancer Res. 2012 Oct;32(10):4423-32.
Affiliation
Abstract
BACKGROUND/AIM: Multidrug resistance poses a serious challenge in cancer therapy. To address this problem, we designed and synthesized Adva-27a, a novel non-ester GEM-difluorinated C-glycoside derivative of podophyllotoxin.
MATERIALS AND METHODS: Adva-27a activity was evaluated in a variety of assays including inhibition of topoisomerase IIa, cytotoxic activity in drug-sensitive and drug-resistant cancer cell lines, metabolic stability in human liver microsomes and pharmacokinetic properties in rats.
RESULTS: Adva-27a exhibited dose-dependent human topoisomerase IIa inhibitory activity and dose-dependent growth inhibitory activity in several drug-sensitive and two multidrug-resistant cancer cell lines. In the multidrug-resistant cell lines, MCF-7/MDR (breast cancer) and H69AR (small-cell lung cancer), Adva-27a was significantly more potent than etoposide. The metabolic stability of Adva-27a in human liver microsomes and its pharmacokinetic properties in rats were better than those of etoposide.
CONCLUSION: Our studies have identified Adva-27a as a novel topoisomerase II inhibitor with superior cytotoxic activity against multidrug-resistant human cancer cells and more desirable pharmacokinetic properties than etoposide.
Dr. Slilaty has been the Chairman of the Board, Chief Executive Officer and President of Sunshine Biopharma, Inc. since October 15, 2009. He founded Qbiogene Inc. in 1991 and Genomics One Corporation in 1995. He was a research team leader of the Biotechnology Research Institute, a division of the National Research Council of Canada. Dr. Slilaty served as a Consultant in a management and advisory capacity for a major Canadian biotechnology company between 1995 and 1997. He has been Member and Chairman of Scientific Advisory Board of Pacific Sunset Investments Inc. since May 17, 2005. He has been the Chairman of the Scientific Advisory Board at Gen-ID Lab Services Inc. since May 17, 2005. He serves as Director of Advanomics Corporation. Dr. Slilaty's other career accomplishments include elucidation of the molecular mechanism for cleavage of LexA, the repressor protein of the E. coli DNA repair system; developing the first site-directed mutagenesis system applicable directly to double-stranded DNA; cloning the gene for the first yeast-lytic enzyme (lytic B-1,3-glucanase); developing a new molecular strategy for increasing the rate of enzyme reactions; inventing the TrueBlue(R) Technology, a powerful new cloning system for accelerating gene discovery and, most recently, developing a new transcriptomics technology for generating entire RNA profiles. He serves as an Adjunct Professor at Universite du Quebec in the Department of Microbiology and Biotechnology. He is an accomplished scientist and a highly skilled business executive. He is cited worldwide and profiled in a variety of reference manuals. Dr. Slilaty is the author of eleven original research papers and four issued (5,071,743; 5,883,244; 6,127,171 and 6,500,619) and one pending (60/532,774) US patents. He has received research grants from the NIH and NSF. He is the recipient of the 1981 award from the University of Arizona Foundation for Meritorious Performance in Teaching. Dr. Slilaty and his vast knowledge of the human genome equips Pacific Sunset with an innovative chairman that can advise Pacific Sunset Investments Inc.'s officers, directors and employees on testing procedures of DNA samples, help better analyze results of the SNPs (SNiPs) studies, and provide overall support to insure the successful implementation of Gen ID's business plan.
Agreed
I prefer he keeps his focus on developing the only TOP 2 drug potential with a 50 billion dollar market potential as opposed to... about as you put it potatoes.
Lots of paperwork still left to take care before that grant money can be put to use. Do you DD.
No it's not!
Dr. Slilaty has been the Chairman of the Board, Chief Executive Officer and President of Sunshine Biopharma, Inc. since October 15, 2009. He founded Qbiogene Inc. in 1991 and Genomics One Corporation in 1995. He was a research team leader of the Biotechnology Research Institute, a division of the National Research Council of Canada. Dr. Slilaty served as a Consultant in a management and advisory capacity for a major Canadian biotechnology company between 1995 and 1997. He has been Member and Chairman of Scientific Advisory Board of Pacific Sunset Investments Inc. since May 17, 2005. He has been the Chairman of the Scientific Advisory Board at Gen-ID Lab Services Inc. since May 17, 2005. He serves as Director of Advanomics Corporation. Dr. Slilaty's other career accomplishments include elucidation of the molecular mechanism for cleavage of LexA, the repressor protein of the E. coli DNA repair system; developing the first site-directed mutagenesis system applicable directly to double-stranded DNA; cloning the gene for the first yeast-lytic enzyme (lytic B-1,3-glucanase); developing a new molecular strategy for increasing the rate of enzyme reactions; inventing the TrueBlue(R) Technology, a powerful new cloning system for accelerating gene discovery and, most recently, developing a new transcriptomics technology for generating entire RNA profiles. He serves as an Adjunct Professor at Universite du Quebec in the Department of Microbiology and Biotechnology. He is an accomplished scientist and a highly skilled business executive. He is cited worldwide and profiled in a variety of reference manuals. Dr. Slilaty is the author of eleven original research papers and four issued (5,071,743; 5,883,244; 6,127,171 and 6,500,619) and one pending (60/532,774) US patents. He has received research grants from the NIH and NSF. He is the recipient of the 1981 award from the University of Arizona Foundation for Meritorious Performance in Teaching. Dr. Slilaty and his vast knowledge of the human genome equips Pacific Sunset with an innovative chairman that can advise Pacific Sunset Investments Inc.'s officers, directors and employees on testing procedures of DNA samples, help better analyze results of the SNPs (SNiPs) studies, and provide overall support to insure the successful implementation of Gen ID's business plan.
Not true!!!
Patience everyone, tomorrow will prove very valuable.. We don't need fluff news here to prove anything. The news of funding etc. will bring us an easy ten bagger. Until then just sit back and relax.
Great all they need now is another 3.5m and then were good to get phase I completed. Another 10m should get us into phase II. You have no clue do you?
The worst part is that he doesn't know what side he's on!
If you know what you own, you don't need to spam. I am just gonna sit back and watch it happen..it will all pay off in the end.
Angel,
Sometimes less is more..
I don't care to attract day flippers. I want strong hands holding on to these shares.
Long and strong #SBFM
GLTA
What news?
Likely to be a busy quarter.
As Norton mentioned, this is a very good loading level, don't think we will revisit these levels again.
Same idea, only much more tangible news / results and dates that are fast approaching this time around.
Seen this before, frenzy is on the rise.
What news??
Closing at 50 cents tomorrow.